Fascination About Tyrosinase-IN-12
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To guage several intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Principal demo objectives were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositi